[{"NetIncomeLoss_1_Q2_USD":759225000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":29806000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q2_USD":622600000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":67101000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0_Q2_USD":55.03,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-629000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-461534000.0,"Depreciation_2_Q2_USD":6300000.0,"Depreciation_1_Q2_USD":3600000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_Q2_USD":54.14,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1074458.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":770000.0,"AssetsCurrent_0_Q2_USD":2620943000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-4417000.0,"FairValueNetAssetLiability_0_Q2_USD":16000000.0,"TreasuryStockShares_0_Q2_shares":195316.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":1694486.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":2332647.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":10909000.0,"TreasuryStockValue_0_Q2_USD":63000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":0.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":0.0,"CommonStockSharesIssued_0_Q2_shares":76273769.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":942800000.0,"Assets_0_Q2_USD":2899519000.0,"ShareBasedCompensation_2_Q2_USD":50423000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":179381000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":213267000.0,"CommonStockParOrStatedValuePerShare_0_Q2_CHF":0.03,"GeneralAndAdministrativeExpense_2_Q2_USD":54323000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q2_USD":34.08,"MarketableSecuritiesCurrent_0_Q2_USD":942800000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-173000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":198842000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":108277000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q2_USD":55.03,"EarningsPerShareBasic_2_Q2_USD":8.57,"EarningsPerShareBasic_1_Q2_USD":10.01,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":80458855.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":80449956.0,"AccountsReceivableNetCurrent_0_Q2_USD":150000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":4718000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":4143000.0,"CommonStockValue_0_Q2_USD":2352000.0,"OtherNonoperatingIncome_2_Q2_USD":2705000.0,"OtherNonoperatingIncome_1_Q2_USD":750000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0_Q2_USD":0.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":9470000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":13427000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_Q2_shares":141351.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":0.007,"EffectiveIncomeTaxRateContinuingOperations_1_Q2_pure":0.005,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":234434000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":289921000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":645516000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":759057000.0,"OtherAssetsNoncurrent_0_Q2_USD":5557000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":1646646000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":175329000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":2529649000.0,"Liabilities_0_Q2_USD":295724000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":21167000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-556000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":6368000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-271000.0,"CommonStockSharesAuthorized_0_Q2_shares":145364335.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":900701000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":715982000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q2_shares":8348539.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":27516000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-168000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":86000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":650780000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":763368000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":28331000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":10000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":5000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":706339000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":75418160.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":75826594.0,"LiabilitiesCurrent_0_Q2_USD":99923000.0,"AccountsPayableCurrent_0_Q2_USD":10145000.0,"NonoperatingIncomeExpense_2_Q2_USD":2705000.0,"NonoperatingIncomeExpense_1_Q2_USD":750000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":31347000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":10000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":6784000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":450000.0,"CashEquivalentsAtCarryingValue_0_Q2_USD":666028000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":1664717000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":686548.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":153000.0,"NumberOfOperatingSegments_2_Q2_Segment":1.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":7533000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":75414000.0,"NetIncomeLoss_2_Q2_USD":646062000.0,"RestrictedCashNoncurrent_0_Q2_USD":18071000.0,"EarningsPerShareDiluted_1_Q2_USD":9.44,"EarningsPerShareDiluted_2_Q2_USD":8.03,"CommonStockSharesOutstanding_0_Q2_shares":76078453.0,"OperatingIncomeLoss_2_Q2_USD":648075000.0,"OperatingIncomeLoss_1_Q2_USD":762618000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":2071000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":135.81,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_Q2_USD":32.97,"LiabilitiesAndStockholdersEquity_0_Q2_USD":2899519000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":15325000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":50423000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":28331000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q2_USD":183600000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":102930000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":15875000.0,"OperatingExpenses_2_Q2_USD":253165000.0,"OperatingExpenses_1_Q2_USD":138083000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":901240000.0,"ProfitLoss_2_Q2_USD":646062000.0,"OtherLiabilitiesCurrent_0_Q2_USD":268000.0,"StockholdersEquity_0_Q2_USD":2603795000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":11775000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":35473000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":943484000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":-5870000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":8348539.0,"TaxesPayableCurrent_0_Q2_USD":4463000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q2_shares":4141831.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":72486000.0,"PropertyPlantAndEquipmentFairValueDisclosure_0_Q2_USD":9340000.0,"MarketableSecurities_0_Q2_USD":980600000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":479249000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":6000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":8697000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":3085000.0,"Ticker":"CRSP","CIK":"1674416","name":"CRISPR THERAPEUTICS AG","OfficialName":"CRISPR Therapeutics AG Common Shares","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"4543904930.0","Country":"Switzerland","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210729"}]